Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Tollys Releases New Preclinical Data Demonstrating Lifelong Potent Anti-tumor Immunity of TL-532
Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a new generation […]
Tollys and Gustave Roussy Enter into New Research Agreement
Tollys, a biopharmaceutical company developing TL-532, the first anti-cancer immunotherapy based on a synthetic toll-like […]
Tollys Accelerates Development of TLR3 Agonist Candidates for Intravenous Administration in Immuno-oncology
Tollys, a biopharmaceutical company developing the first anti-cancer immunotherapy based on a synthetic Toll-Like Receptor […]
Tollys Presents Scientific Data Supporting Preclinical Proof of Concept for TL-532, Its Cancer Immunotherapy Drug Candidate
Tollys, a biopharmaceutical company developing TL-532, the first synthetic specific agonist of Toll-like Receptor 3 […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more